Eli Lilly and Company Profit Margin

The latest profit margin for LLY.TO is 31.86% as of September 2026. That compares with 30.99% in the prior-year period — up 2.8% year over year. That is above the Healthcare sector average of 9.48%. Investors often review this figure alongside Eli Lilly and Company's historical trend and sector peers before judging valuation or financial health.

Over the past year, LLY.TO's profit margin moved from 30.99% to 31.86% — a 2.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eli Lilly and Company's valuation or profitability profile.

Against Healthcare companies, LLY.TO currently prints 31.86% for profit margin, while the sector average sits near 9.48%. That is roughly 236.1% above the sector mean. Large gaps often invite a closer look at Eli Lilly and Company's growth, margins, and balance sheet.

Profit Margin shows how effectively Eli Lilly and Company converts resources into returns. At 31.86%, LLY.TO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 30.99% in the prior-year period — up 2.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LLY.TO's profit margin (31.86%), review year-over-year change from 30.99%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.